The publication of this content was funded by Menarini Stemline. The views and opinions expressed are exclusively those of the speakers.
The symposium is intended for HCPs only.
Menarini Stemline’s key symposium from the 2024 European Society for Medical Oncology (ESMO) Congress, focused on treatment strategies for patients with advanced/metastatic ER+/HER2- breast cancer who have progressed after initial endocrine therapy with CDK4/6 inhibitors.
Expert clinicians discussed the current ESMO recommendations for second-line and subsequent treatments, which are based on endocrine sensitivity status and biomarkers. Trial data supporting these recommendations were presented, along with the associated benefits and risks.
Speakers:
Peter Schmid1
Virginia Kaklamani2
Frederik Marmé3
1. Chair in Cancer Medicine, Barts Cancer Institute, Queen Mary University London, UK; Clinical Director of the Breast Cancer Centre at the St. Bartholomew Cancer Centre, and Honorary Consultant Medical Oncologist, Barts Hospital, London, UK
2. Professor of Medicine, Division of Hematology/Oncology, University of Texas Health Sciences Center, San Antonio, Texas, USA; and Leader of the Breast Cancer Program, Mays Cancer Center, San Antonio, Texas, USA
3. Professor of Experimental and Translational Gynecologic Oncology at the Medical Faculty, and Head of the Section Conservative Gynecologic Oncology and the Gynecologic Clinical Trials Unit, University Hospital Mannheim, Heidelberg University, Germany; Co-chair of the AGO Study Group; and member of the Scientific Board of the German Breast Group (GBG)
